Sign In

Login

Password

Forgot Password ? Sign Up

Roxadustat (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Roxadustat" in German language version.

refsWebsite
Global rank German rank
8nih.gov
4th place
7th place
6doi.org
2nd place
3rd place
3astrazeneca.com
low place
low place
2g-ba.de
low place
1,618th place
2europa.eu
68th place
29th place
1aerzteblatt.de
3,043rd place
200th place
1astellas.com
low place
low place
1fiercepharma.com
low place
low place
1karger.com
4,489th place
3,288th place
1harvard.edu
18th place
181st place
1dshs-koeln.de
low place
2,595th place

aerzteblatt.de

astellas.com

astrazeneca.com

doi.org

  • Zuo-Lin Li, Yan Tu, Bi-Cheng Liu: Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. In: Kidney Diseases. Band 6, Nr. 2, 2020, S. 65–73, doi:10.1159/000504850, PMID 32309288, PMC 7154284 (freier Volltext) – (karger.com [abgerufen am 10. Juli 2022]).
  • Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP: Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. In: The New England Journal of Medicine. 381. Jahrgang, Nr. 11, September 2019, S. 1001–1010, doi:10.1056/NEJMoa1813599, PMID 31340089.
  • Nan Chen, Chuanming Hao, Bi-Cheng Liu, Hongli Lin, Caili Wang: Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. In: The New England Journal of Medicine. Band 381, Nr. 11, 12. September 2019, S. 1011–1022, doi:10.1056/NEJMoa1901713.
  • Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch RE, Sun J, Yuan Q: The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model. In: Scientific Reports. 9. Jahrgang, Nr. 1, April 2019, S. 6035, doi:10.1038/s41598-019-41924-5, PMID 30988335, PMC 6465281 (freier Volltext), bibcode:2019NatSR...9.6035Z.
  • Cygulska K, Wejner-Mik P, Plewka M, Figiel Ł, Chrzanowski Ł, Kasprzak JD: Roxadustat: another drug that causes pulmonary hypertension? Report of first human case. In: Polish Archives of Internal Medicine. 129. Jahrgang, Nr. 5, Mai 2019, S. 344–345, doi:10.20452/pamw.4445, PMID 30758318.
  • Daniel Eichner, Ryan M. van Wagoner, Mitch Brenner, James Chou, Scott Leigh, Lee R. Wright, Lee A. Flippin, Michael Martinelli, Oliver Krug, Wilhelm Schänzer, Mario Thevis: Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. In: Drug Testing and Analysis, Jahrgang 9, Nummer 11–12, 4. April 2017, S. 1768–1778, pmid:28378453, doi:10.1002/dta.2202.

dshs-koeln.de

europa.eu

ec.europa.eu

ema.europa.eu

fiercepharma.com

g-ba.de

harvard.edu

ui.adsabs.harvard.edu

karger.com

  • Zuo-Lin Li, Yan Tu, Bi-Cheng Liu: Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. In: Kidney Diseases. Band 6, Nr. 2, 2020, S. 65–73, doi:10.1159/000504850, PMID 32309288, PMC 7154284 (freier Volltext) – (karger.com [abgerufen am 10. Juli 2022]).

nih.gov

ncbi.nlm.nih.gov

  • Zuo-Lin Li, Yan Tu, Bi-Cheng Liu: Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. In: Kidney Diseases. Band 6, Nr. 2, 2020, S. 65–73, doi:10.1159/000504850, PMID 32309288, PMC 7154284 (freier Volltext) – (karger.com [abgerufen am 10. Juli 2022]).
  • Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP: Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis. In: The New England Journal of Medicine. 381. Jahrgang, Nr. 11, September 2019, S. 1001–1010, doi:10.1056/NEJMoa1813599, PMID 31340089.
  • Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch RE, Sun J, Yuan Q: The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model. In: Scientific Reports. 9. Jahrgang, Nr. 1, April 2019, S. 6035, doi:10.1038/s41598-019-41924-5, PMID 30988335, PMC 6465281 (freier Volltext), bibcode:2019NatSR...9.6035Z.
  • Cygulska K, Wejner-Mik P, Plewka M, Figiel Ł, Chrzanowski Ł, Kasprzak JD: Roxadustat: another drug that causes pulmonary hypertension? Report of first human case. In: Polish Archives of Internal Medicine. 129. Jahrgang, Nr. 5, Mai 2019, S. 344–345, doi:10.20452/pamw.4445, PMID 30758318.
  • Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A: Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: Investigation on a positive case., J Pharm Biomed Anal. 2016 Mar 20;121:181-187, PMID 26808067.
  • Mathew B, Philip M, Perwad Z, Karatt TK, Caveney MR, Subhahar MB, Karakka Kal AK: Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control., Drug Test Anal. 2021 Jun;13(6):1203-1215, PMID 33569900.
  • Saigusa D, Suzuki N, Matsumoto Y, Umeda K, Tomioka Y, Koshiba S, Yamamoto M: Detection of novel metabolite for Roxadustat doping by global metabolomics., J Biochem. 2018 Feb 9. PMID 29438490.
  • Daniel Eichner, Ryan M. van Wagoner, Mitch Brenner, James Chou, Scott Leigh, Lee R. Wright, Lee A. Flippin, Michael Martinelli, Oliver Krug, Wilhelm Schänzer, Mario Thevis: Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. In: Drug Testing and Analysis, Jahrgang 9, Nummer 11–12, 4. April 2017, S. 1768–1778, pmid:28378453, doi:10.1002/dta.2202.